Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.

ABSTRACT:

Importance

Patients with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) less than 40% who experience LVEF improvement to 40% or higher (HFimpEF) may still face residual risks.

Objective

To assess the clinical profiles, risk, and treatment response to finerenone in participants with HFimpEF.

Design, setting, and participants

A total of 6001 patients with HE, LVEF of 40% or higher, New York Heart Association class II to IV symptoms, and elevated natriuretic peptide levels, were enrolled between September 14, 2020, and January 10, 2023. Patients with a prior history of LVEF less than 40% were included. Data analysis was conducted between September 1 to December 10, 2024.

Intervention

Participants received finerenone (titrated to 20 mg or

SUBMITTER: Pabon MA 

PROVIDER: S-EPMC12096322 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature